TRANSCURE-BIOSERVICES
3.6.2019 14:57:05 CEST | Business Wire | Press release
TransCure bioServices (France), a one-stop-shop preclinical services company dedicated to in-vivo full human immune system mouse models, today announced that it has completed a 2.5 million euros funding with Financière Arbevel (France). This financing round will enable the company, healthy and profitable for the last three years, to accelerate its international sales growth as well as to expand in vivo preclinical pharmacology services offers into new product lines.
This financing was entirely subscribed by Arbevel Life Sciences Crossover I, a european private equity fund based in Paris (France) with a cross-over approach. TransCure bioServices will use the proceeds to expand its profitable business activities in Europe and the USA, and to develop additional platforms for international pharmaceutical and biotech companies.
Marc Le Bozec , Managing Director of Arbevel Life Sciences Crossover I Fund, will now join the Supervisory Board of the company and commented: “We are excited to collaborate with TransCure bioServices’ management in expediting its growth by addressing new markets and strengthening its commercial team”.
Patrick Nef , Chief Executive Officer and co-founder of TransCure bioServices, commented: “We welcome Arbevel as a new shareholder to boost our healthy and profitable international CRO business which generated significant growth over the past 3 years. In addition to the ongoing full human immune system mouse models for immuno-oncology, inflammation, and infectious diseases we are excited to develop new hu-liver and 100% human monoclonal antibody services. We look forward to the contribution of Marc Le Bozec in the Supervisory Committee and to benefit from his expertise of preclinical CRO business and financial markets.”
“Arbevel’s investment underlines a steppingstone for the growth of our worldwide business,” says Stéphane Legastelois , Chairman of TransCure bioServices. “It allows TransCure bioServices to widen its range of services and to investigate new exciting areas in the field of full human antibodies.”
Agile Capital Markets acted as financial advisor for TransCure bioServices in this transaction.
About TransCure bioServices SAS.
TransCure bioServices SAS is a European CRO based in France offering pre-clinical in vivo pharmacology fee-for-services to international pharmaceutical, biotech and academic customers. Uniquely designed full human immune system and hu-liver mouse models provide predictive power for drug profiling and smarter drug candidate selection for immuno-oncology, inflammation (IBD, SLE, MS, RA), auto-immune, infectious (HIV), liver diseases, and vaccines. If you are looking for check point inhibition, CART-cell designs, 100% IgG mAb, any drug profiling involving the human immune system or hu-liver, contact us at www.tcbioservices.com
About Financière Arbevel
Founded in 1997, Financière Arbevel, an entrepreneurial investment management company, has grown significantly since its takeover by the current owners in early 2009 – the AUM progressed from EUR 25m to EUR 1.6bn as of today (of which EUR 732m under the umbrella SICAV “Pluvalca” comprising 9 sub-funds). The company currently employs a total of 34 staff, of which 13 are dedicated to fund management/investment research. Financière Arbevel is recognized for its expertise within the small & mid cap asset class. We are a research-driven organization with a strong emphasis on fundamental financial and strategic analysis, close relationships with top managements of listed companies (more than 1000 company meetings last year) and a permanent quest for new investment themes offering structural growth opportunities. The digitalization, fintech, Industry 4.0, or the ageing of the world population are some of our favorite investment themes. We ensure we 3/3 are following closely the latest developments within this universe, by participating in various conferences, trade fairs, sector-specific thematic events and by meeting regularly with managements of listed companies. Our small & mid cap DNA is spread across various strategies under the PLUVALCA family of funds with a cross-asset approach comprising our core equity funds, thematic equity funds, fixed income and diversified/flexible allocation funds). In 2015, the Norwegian sovereign wealth fund chose Financière Arbevel to manage its French equity mandate. In 2018, Financière Arbevel pursued its development by launching its first European private equity fund (FPCI form or “Professional private equity investment fund”) with a cross-over approach focused on the non-listed life-science universe, with the idea of accompanying a limited number of biotechnology start-ups in their development. www.arbevel.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190603005005/en/
Contact:
TransCure bioServices SAS Patrick Nef, PhD Chief Executive Officer Email: info@tcbioservices.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TTNE Announces the World Sauna Award “SAUNA37 2026”10.3.2026 04:00:00 CET | Press release
TTNE Inc. today announced “SAUNA37 2026”, the world sauna award recognizing 37 sauna destinations worldwide This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260308149186/en/ SAUNA37 Through this initiative, we aim to contribute to the global growth of sauna culture and create a future where people around the world can lead happier and healthier lives through saunas. TTNE was founded by Totonoe Oyakata (Dai Matsuo) and Sauna Master (Daisuke Akiyama), who have personally experienced some of the world's finest saunas. Their desire to establish a similar deep-rooted sauna culture in Japan led to the creation of TTNE. As people once again have the opportunity to explore sauna experiences around the world, SAUNA37 aims to introduce the diverse and unique sauna facilities and cultures across the globe. Through this initiative, we seek to further evolve Japan’s sauna culture while also sharing it with the world. TTNE remains committed
Hexagon Semi’s HX77 AR Display Processor Achieves Ultra-Low Power Consumption with VeriSilicon’s Nano IP Portfolio10.3.2026 01:00:00 CET | Press release
VeriSilicon’s Mature GPU, Display Processing, and DeWarp IPs Collaboratively EnableHighlyIntegrated, Low-Latency AR Display Processing VeriSilicon (688521.SH) today announced that Hefei Hexagon Semiconductor (Hexagon Semi), an image processing SoC provider, has adopted VeriSilicon’s proven IP portfolio in its high-performance HX77 series image processing SoC. The adopted IPs include the GCNanoUltraV 2.5D Graphics Processing Unit (GPU) IP, DW100 DeWarp Processing IP, and DC9200Nano Display Processing IP. The SoC has successfully taped out, achieving a first-pass silicon success. The HX77 series is a highly integrated, low-power image processing SoC based on RISC-V architecture, integrating comprehensive video input/output interfaces, image processing, and system control capabilities. By leveraging an innovative heterogeneous computing architecture and sophisticated power management technology, HX77 has successfully achieved a technological breakthrough that enables 2K@60fps output with
Operio Group Named Distributor for Schaefer Technologies in the United Kingdom and European Union9.3.2026 22:00:00 CET | Press release
Operio Group has signed a distribution agreement with Schaefer Technologies, a manufacturer of semi-automatic encapsulation equipment. Operio Group, a holding company building a global group of brands serving the solid dose manufacturing industry, will be the official distributor of Schaefer Technologies’ products in the United Kingdom and the European Union. Schaefer Technologies develops semi-automatic capsule filling systems, including equipment that produces banded capsules for liquid and pellet formulations used by nutraceutical and pharmaceutical manufacturers. Leadership from both companies worked together to establish the agreement, including Kevin Schaefer, CEO of Schaefer Technologies Inc., and Alastair Sanderson, Chief Business Development Officer at Operio Group. “Schaefer Technologies is looking forward to our new relationship with Operio Group,” said Schaefer. “Their understanding of the pharmaceutical equipment market makes them a strong partner as we combine our experti
Kinaxis Goes All-In on Innovation at Upcoming Kinexions in Las Vegas9.3.2026 19:00:00 CET | Press release
Annual customer conference will bring together global supply chain leaders to explore the latest trends, best practices and technologies in AI-powered planning, decision-making and agentic innovation Registration is officially open for Kinexions North America, the premier global supply chain orchestration conference hosted by Kinaxis® Inc. (TSX: KXS). Taking place June 1–3 in Las Vegas, Nevada, the event brings together supply chain leaders, innovators and practitioners from around the world to explore how organizations can leverage AI-driven strategies and technologies to connect data, people and decisions. After a year defined by market volatility, geopolitical risk and disruption, this year’s conference will focus on how intelligent supply chain orchestration enables organizations to move beyond reactive planning to building true enterprise adaptability. The program promises to be the most immersive and future-forward Kinexions yet, with renowned author, entrepreneur and innovation
InterSystems Appoints Former NHS and Mass General Leader Dr. Tim Ferris as Vice President, Healthcare Practice9.3.2026 17:00:00 CET | Press release
InterSystems, a creative data technology provider powering more than one billion health records globally, today announced the appointment of Tim Ferris, M.D., as Vice President, Healthcare Practice. The announcement comes as healthcare leaders gather for the 2026 HIMSS Global Health Conference & Exhibition. In this role, Dr. Ferris will leverage his comprehensive view of the industry to help drive the clinical and strategic direction of the company’s healthcare solutions worldwide. Drawing on his vast experience, he will serve as a strategic advisor to global health systems and governments, engineer targeted technology solutions based on real-world executive needs, advance his academic research on health data architecture and lead public discourse on the intersection of AI and care delivery. Dr. Ferris brings a unique global perspective to InterSystems that is virtually unmatched in healthcare. His career spans 30 years as a practicing primary care physician, executive leadership at pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom